AbstractUterine leiomyoma is one of the most common benign hyperproliferative diseases of the female reproductive organs. According to the literature, its prevalence among women of reproductive age is estimated to be approximately 20–40%. Moreover, it is diagnosed more often (up to 75-85%) when carrying out morphological investigations of macro specimens after hysterectomy. In recent years the proportion of young patients with this pathology has increased. For a long period of time radical hysterectomy has been the most common method used to treat the disease. During the past decades the possibilities of organ-preserving treatment of the disease expanded due to the achievements of modern pharmaceutical industry and implementation of new technologies. As a result, surgical interventions themselves changed and the proportion of surgeries such as conservative myomectomy, uterine artery embolization, hysteroscopic resection of submucous fibroid increased. The data on surgical interventions allowed us to eradicate the symptoms of uterine leiomyoma preserving fertility in many patients, however, the risk of tumor recurrence and growth is still present. The recurrence rate after organ-preserving surgeries remains high and, according to the results of various studies, accounts for 2-50% of cases. Considering the above-mentioned data prevention of tumor recurrence is of great relevance. Based on the results of diagnostic program including endocrinologic, immunological and morphological investigations there was found that in women with isolated uterine leiomyoma dyshormonal disease, inflammatory processes of the genital organs, chronic endometritis, pathology of the receptor apparatus of uterine tissues occur more often; hyperprolactinemia, relative or absolute hyperestrogenemia and increased production of antibodies are more often diagnosed in women with uterine leiomyoma and co-existent dyshormonal pathology of the mammary and thyroid gland. According to the literature, in isolated uterine leiomyoma therapy aimed at correcting local factors including anti-inflammatory therapy, local hormone therapy or uterine artery embolization is recommended. In comorbidity correction of systemic metabolic disorders, namely anti-stress therapy, systemic hormone therapy, immune system correction, treatment of co-existent somatic pathology which may include local use of hormones and organ-preserving surgical interventions should be performed first of all. Thus, modern medicine has in its arsenal various organ-preserving, conservative, surgical including minimally invasive methods of treatment implementation of which allows us to improve quality of life in such patients as well as to enhance fertility and reproductive health of women.
Zadonskaya YuN, Sykhikh GT, Dobrokhotova YuE, Venediktova MG, Litvinova NA, Demura TA. Effects of indinol and epigallat on processes of cell proliferation and apoptosis in hyperplasic endometrium of premenopausal women. IV Vserossiyskiy nauchnyy Forum “Mat i ditya”. Moscow. 2008; 358.
Kosei NV. Optimization of organ-preserving treatment of uterine leiomyoma using the levonorgestrel-releasing intrauterine system. Zdorovye zhenshchiny. 2007;3(31):91-97
Kosei NV. Phytotherapy in treatment of dyshormonal benign tumors of mammary gland in women with uterine leiomyoma. Reproduktivnoye zdorovye zhenshchiny. 2008;4(38):171-173.
Mayorov MV. Uterine fibroid: surgical extremism or medicated conservatism? Provisor. 2002;7:36-38.
Potapov VO, Medvediev MV, Donska YuV, Ruban NK. Prediction of recurrent uterine leiomyoma and efficacy of various methods of organ-preserving treatment. Medychni perspektyvy. 2012;17(4):44-48.
Samoylova TE, Volkov OI, Kokov LS. Uterine artery embolization in treatment of uterine leiomyoma. Annaly khirurgiyi. 2003;4:12-17.
Sidorova I. The role of growth factors and extracellular matrix in the pathogenesis of simple and proliferative uterine fibroid. Vrach. 2004;1:30-31.
Solskyi YaP, Tatarchuk TF, Kosei NV, Lutsenko SI. Experience in using gonadotropin-releasing hormones in treatment of uterine fibroid. Zdorovye zhenshchiny. 2001;1:40-45.
Tatarchuk TF, Kosei NV, Islamova AO. Thyroid homeostasis and dyshormonal disorders of female reproductive system. Endokrinnaya ginekologiya (klinicheskie ocherki). Tatarchuk TF, Solskyi YaP, editors. Zapovit. Kyiv. 2003;200-216.
Tatarchuk TF, Kosei NV, Mohylevskyi DM, Sukhorerbraya EI, Shakalo IN. Modern aspects of organ-preserving therapy of uterine leiomyoma. Reproduktivnoye zdorovye zhenshchiny. 2006;1(25):123-129.
Tatarchuk TF, Zadorozhna TD, Mohylevskyi DM, Kosei NV. Clinical and morphological criteria for uterine leiomyoma in women of late reproductive age. Ukraiinskyi morfolohichnyi almanakh. 2006;4(3):85-88.
Tatarchuk TF, Kosei NV. Organ-preserving therapy for uterine leiomyoma (differentiated approaches). Liky Ukraiiny. 2008;9(125-126):36-40.
Tatarchuk TF, Kosei NV, Ganzhiy IYu. Adipose tissue and female reproductive system. Reproduktivnoye zdorovye zhenshchiny. 2008;5(39):49-58.
Khominska ZB, Vasylchuk HM, Kosei NV, Mohylevskyi DM. Peculiarities of general and local hormonal homeostasis in women with endometrial hyperplasia during perimenopause. Visnyk Vinnytskoho derzhavnoho universytety. 2003;1/2:353-354.
Garry R, Shett S, Sutton C. Which hysterectomy? A detailed comprasion of laparoscopic, vaginal and abdominal hysterectomy. Menorrhagia. Iss Medical Media Ltd. 1999;239-252.
Phillips DR, Shett S, Sutton C. Fibroids and menorrhagia: the role of myolysis. Menorrhagia. Iss Medical Mtdia Ltd. 1999;164-165.
Sabry M, Al-Hendy A. Innovative Oral Treatments of Uterine Leiomyoma. Obstetrics and Gynecology International 2012;2012:1-10. Available from: http://www.hindawi.com/journals/ogi/2012/943635 PubMed PMID: 22518167. doi: 10.1155/2012/943635.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.